Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.10.4353

Molecular Target Therapy of AKT and NF-kB Signaling Pathways and Multidrug Resistance by Specific Cell Penetrating Inhibitor Peptides in HL-60 Cells  

Davoudi, Zahra (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Akbarzadeh, Abolfazl (Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Rahmatiyamchi, Mohammad (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Movassaghpour, Ali Akbar (Hematology and Oncology Research Center, Tabriz University of Medical Sciences)
Alipour, Mohsen (Department of Physiology, Faculty of Medicine, Zanjan University of Medical Sciences)
Nejati-Koshki, Kazem (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Sadeghi, Zohre (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Dariushnejad, Hassan (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Zarghami, Nosratollah (Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.10, 2014 , pp. 4353-4358 More about this Journal
Abstract
Background: PI3/AKT and NF-kB signaling pathways are constitutively active in acute myeloid leukemia and cross-talk between the two has been shown in various cancers. However, their role in acute myeloid leukemia has not been completely explored. We therefore used cell penetrating inhibitor peptides to define the contributions of AKT and NF-kB to survival and multi drug resistance (MDR) in HL-60 cells. Materials and Methods: Inhibition of AKT and NF-kB activity by AKT inhibitor peptide and NBD inhibitor peptide, respectively, resulted in decreased expression of mRNA for the MDR1 gene as assessed by real time PCR. In addition, treatment of HL-60 cells with AKT and NBD inhibitor peptides led to inhibition of cell viability and induction of apoptosis in a dose dependent manner as detected by flow cytometer. Results: Finally, co-treatment of HL-60 cells with sub-optimal doses of AKT and NBD inhibitor peptides led to synergistic apoptotic responses in AML cells. Conclusions: These data support a strong biological link between NF-kB and PI3-kinase/AKT pathways in the modulation of antiapoptotic and multi drug resistant effects in AML cells. Synergistic targeting of these pathways using NF-kB and PI3-kinase/AK inhibitor peptides may have a therapeutic potential for AML and possibly other malignancies with constitutive activation of these pathways.
Keywords
AKT/PKB; NF-kB; cell penetrating peptides; AML; MDR; therapy;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Akbarzadeh A, Samiei M, Davaran S, et al (2012). Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett, 7, 14-26.   DOI   ScienceOn
2 Akbarzadeh A, Zarghami N, Mikaeili H, et al (2012). Synthesis, characterization and in vitro evaluation of novel polymercoated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl, 5, 13-25.
3 Al-Bahar S, Adriana Z, Pandita R (2008). Acute myeloid leukemia as a genetic disease. Gulf J Oncolog, 3, 9-15.
4 Altman JK, Sassano A, Platanias LC (2011). Targeting mTOR for the treatment of AML: New agents and new directions. Oncotarge, 2, 510-7.
5 Bentires-Alj M, Barbu V, Fillet M, et al (2003). NF-kB transcription factor induces drug resistance through MDR1expression in cancer cells. Oncogene, 22, 90-7.   DOI
6 Akbarzadeh A, Mikaeili H, Zarghami N, et al (2012). Preparation and in-vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymer. Int J Nanomedicine, 7, 1-16.   DOI   ScienceOn
7 Akbarzadeh A, Nejati-Koshki K, Mahmoudi Soghrati M, et al (2013). In vitro studies of NIPAAM-MAA-VP copolymercoated magnetic nanoparticles for controlled anticancer drug release. JEAS, 3, 108-15.   DOI
8 Akbarzadeh A, Omidfar K, Ahmadin A, et al (2014). An electrochemical immunosensor for digoxin using core-shell gold coated magnetic nanoparticles as labels. Mol Biol Rep, 41, 1659-68.   DOI
9 Akbarzadeh A, Pourhassan-Moghaddam M, Rahmati-Yamchi M, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett, 8, 485-95.   DOI
10 Nejati-Koshki K, Zarghami N, Pourhassan-Moghaddam M, et al (2012). Inhibition of leptin gene expression and secretion by silibinin: possible role of estrogen receptors. Cytotechnology, 64, 719-26.   DOI   ScienceOn
11 Nejati-Koshki K, Akbarzadeh A, Pourhasan-Moghaddam M, et al (2013). Inhibition of leptin and leptin receptor gene expression by silibinin-curcumin combination. Asian Pac J Cancer Prev, 14, 6595-9.   과학기술학회마을   DOI   ScienceOn
12 Norgaard JM, Hokland P (2000). Biology of multiple drug resistance in acute leukemia. Int J Hematol, 72, 290-7.
13 Orange JS, May MJ (2008). Cell penetrating peptide inhibitors of Nuclear Factor-kappa B. Cell Mol Life Sci, 65, 3564-91.   DOI
14 Akbarzadeh A, Rezaei A, Nejati-Koshki K, et al (2014). Synthesis and physicochemical characterization of biodegradable star-shaped poly lactide-co-glycolide- $\beta$-cyclodextrin copolymer Nanoparticles Containing Albumin, J Adv Nanoparticles, 3, 1-9.   DOI
15 Akbarzadeh A, Rezaei-Sadabady R, Zarghami N, et al (2013). Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxytyrosol derivatives indicated by quantum chemical calculations. Soft, 2, 13-8.   DOI
16 Park S, Chapuis N, Tamburini J, et al (2010). Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica, 95, 819-28.   DOI
17 Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30.   DOI   ScienceOn
18 Scholl C, Gilliland DG, Frohling S (2008). Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol, 35, 336-45.   DOI   ScienceOn
19 Tas SW, de Jong EC, Hajji N, et al (2005). Selective inhibition of NF-jB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur J Immuno, 35, 1164-74.   DOI   ScienceOn
20 Ta-Gan Y, Hurevich M, Klein S, et al (2011). Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt). J Med Chem, 54, 5154-64.   DOI   ScienceOn
21 Thanos D, Maniatis T (1995). NF-kappa B: a lesson in family values. Ce, 80, 529-32.
22 Tho F, Ganser A (2011). Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives. Front Med China, 4, 356-62.
23 Ebrahimnezhad Z, Zarghami N, Keyhani M, et al (2013). Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-Fe3O4 in T47D breast cancer cell line. Bioimpacts, 3, 67-74.
24 Bixby D, Talpaz M (2009). Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematol Am Soc Hematol Educ Program, 1, 461-76.
25 Caceres-Cortes JR (2013). Blastic Leukaemias (AML) :A Biologist s view. Cell Biochem Biophys, 66, 13-22.   DOI   ScienceOn
26 Chuang JC, Sheu GT, Wang PC, et al (2012). Docetaxel and 5-fluorouracil induce human p53 tumor suppressor gene transcription via a short sequence at core promoter element. Toxicol in Vitro, 26, 678-85.   DOI
27 Harris F, Dennison SR, Singh J, et al (2013). On the selectivity and efficacy of defense peptides with respect to cancer cells. Med Res Re, 33, 190-234.   DOI
28 Eldar-Finkelman H, Eisenstein M (2009). Peptide inhibitors targeting protein kinases. Curr Pharm Des, 15, 2463-70.   DOI
29 Furumai R, Komatsu Y, Nishino N, et al. (2001). Potent histone deacetylase inhibitors built from trichostatin. Proc Natl Acad Sci USA, 98, 87-92.   DOI   ScienceOn
30 Grandage VL, Gale RE, et al (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NFkB, MAPkinase and p53 pathways. Leukemia, 19, 586-94.
31 Leith CP, Kopecky KJ, Godwin J, et al (1997). Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy ASouthwest Oncology Group Study. Blood, 89, 3323-9.
32 Akbarzadeh A, Samiei M, Joo SW, et al (2012). Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol, 10, 46-52.   DOI
33 Akbarzadeh A, Ghasemali S, Nejati K, et al (2013). Study of inhibitory effect of $\beta$-cyclodextrin-helenalin complex on HTERT gene expression in T47D breast cancer cell line by real time quantitative PCR (q-PCR). Asian Pac J Cancer Prev, 14, 6949-53.   과학기술학회마을   DOI   ScienceOn
34 Akbarzadeh A, Hosseininasab S, Davaran S, et al (2014). Synthesis, characterization, and In vitro studies of PLGAPEG nanoparticles for oral Insulin delivery. Chem Biol Drug Des, 3, 1-9.
35 Caceres-Cortes JR (2013). Blastic leukaemias (AML): a biologist s view. Cell Biochem Biophys, 66, 13-22.   DOI   ScienceOn
36 Wang Y, Liu X, Zhang HT, et al (2007). NF-kappaB regulating expression of mdr1 gene and P-gp to reverse drug-resistance in leukemic cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 15, 950-4.
37 Weisburg JH (2008). Multidrug resistance in acute myeloid leukemia: potential new therapeutics. J Nucl Med, 49, 1405-7.   DOI   ScienceOn
38 Zeng Z, Sarbassov dos D, Samudio IJ, et al (2007). Rapamycin derivatives reduce mTORC2 signaling and inhibitAKT activation inAML. Blood, 109, 3509-12.   DOI   ScienceOn
39 Levitzki A, Klein S (2010). Signal transduction therapy of cancer. Mol Aspects Med, 31, 287-329.   DOI   ScienceOn
40 Licht JD, Sternberg DW (2005). The molecular pathology of acute myeloid leukemia. Hematol Am Soc Hematol Educ Program, 1, 137-42.
41 Lowenberg B, Downing J, Burnett A (1999). Acute myeloid leukaemia. N Engl J Med, 341, 1051-62.   DOI   ScienceOn
42 Miyamoto S (2011). Nuclear initiated NF-$\kappa{B}$ signaling: NEMO and ATM take center stage. Cell Res, 21, 116-30.   DOI   ScienceOn
43 Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-8.   과학기술학회마을   DOI   ScienceOn
44 Kumar CC, Madison V (2005). AKT crystal structure and AKTspecific inhibitors. Oncogene, 24, 7493-501.   DOI   ScienceOn
45 Birkenkamp KU, Geugien M, Schepers H, et al (2004). Constitutive NF-jB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia, 18, 103-12.   DOI
46 Nasiri M, Zarghami N, Koshki KN, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pac J Cancer Prev, 14, 3449-53.   과학기술학회마을   DOI   ScienceOn